These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 28621766)

  • 21. Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis.
    Atkins HL; Freedman MS
    Neurotherapeutics; 2017 Oct; 14(4):888-893. PubMed ID: 28822119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Suppression of Circulating Proinflammatory Cytokines in Multiple Sclerosis Patients Following Autologous Haematopoietic Stem Cell Transplantation.
    Hendrawan K; Khoo MLM; Visweswaran M; Massey JC; Withers B; Sutton I; Ma DDF; Moore JJ
    Front Immunol; 2021; 12():782935. PubMed ID: 35126353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.
    Das J; Snowden JA; Burman J; Freedman MS; Atkins H; Bowman M; Burt RK; Saccardi R; Innocenti C; Mistry S; Laud PJ; Jessop H; Sharrack B
    Mult Scler; 2021 Jul; 27(8):1198-1204. PubMed ID: 33565902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
    Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
    Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
    Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory B cells in systemic sclerosis patients.
    Lima-Júnior JR; Arruda LCM; Gonçalves MS; Dias JBE; Moraes DA; Covas DT; Simões BP; Oliveira MC; Malmegrim KCR
    Rheumatology (Oxford); 2021 Dec; 60(12):5538-5548. PubMed ID: 33724344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - a guide for the generalist.
    Snowden JA; Sharrack B; Akil M; Kiely DG; Lobo A; Kazmi M; Muraro PA; Lindsay JO
    Clin Med (Lond); 2018 Aug; 18(4):329-334. PubMed ID: 30072560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defective expression of apoptosis-related molecules in multiple sclerosis patients is normalized early after autologous haematopoietic stem cell transplantation.
    de Oliveira GL; Ferreira AF; Gasparotto EP; Kashima S; Covas DT; Guerreiro CT; Brum DG; Barreira AA; Voltarelli JC; Simões BP; Oliveira MC; de Castro FA; Malmegrim KC
    Clin Exp Immunol; 2017 Mar; 187(3):383-398. PubMed ID: 28008595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients' expectations of autologous hematopoietic stem cell transplantation as a treatment for MS.
    De Kleermaeker FGCM; Uitdehaag BMJ; van Oosten BW
    Mult Scler Relat Disord; 2020 Jan; 37():101467. PubMed ID: 31678857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detailed immunophenotyping of the hematopoietic graft from patients with multiple sclerosis undergoing autologous hematopoietic stem cell transplant.
    Massey J; Visweswaran M; Khoo M; Hendrawan K; Sutton I; Withers B; Ma D; Moore J
    Cytotherapy; 2023 Dec; 25(12):1271-1276. PubMed ID: 37737765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis.
    Bose G; Freedman MS
    J Neurol Sci; 2021 Feb; 421():117324. PubMed ID: 33497951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists.
    Das J; Sharrack B; Snowden JA
    Curr Hematol Malig Rep; 2019 Apr; 14(2):127-135. PubMed ID: 30828772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
    Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS
    Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis.
    Chatterton S; Withers B; Sutton IJ; Milliken ST; Ma DD; Moore JJ; Massey JC
    Mult Scler; 2021 Nov; 27(13):2112-2115. PubMed ID: 33870788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
    Boffa G; Lapucci C; Sbragia E; Varaldo R; Raiola AM; Currò D; Roccatagliata L; Capello E; Laroni A; Mikulska M; Gualandi F; Uccelli A; Angelucci E; Mancardi GL; Inglese M
    Eur J Neurol; 2020 Oct; 27(10):2047-2055. PubMed ID: 32418281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Immunoablation and Autologous Hematopoietic Stem Cell Transplantation on Treatment Cost of Multiple Sclerosis: Real-World Nationwide Study.
    Orlewska K; Bogusz K; Podlecka-Piętowska A; Nojszewska M; Markiewicz M; Liwoch R; Orlewski P; Śliwczyński A; Zakrzewska-Pniewska B; Snarski E
    Value Health Reg Issues; 2021 Sep; 25():104-107. PubMed ID: 33865219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis Society.
    Miller AE; Chitnis T; Cohen BA; Costello K; Sicotte NL; Stacom R;
    JAMA Neurol; 2021 Feb; 78(2):241-246. PubMed ID: 33104165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunoablative therapy followed by autologous hematopoietic stem cell transplantation as the first-line disease-modifying therapy in patients with multiple sclerosis.
    Lachnit M; Revendova KZ; Hradilek P; Bunganic R; Koristek Z; Jelinek T; Skutova M; Piza R; Volny O; Hajek R; Bar M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2024 Mar; 168(1):50-54. PubMed ID: 37337857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis.
    Ge F; Lin H; Li Z; Chang T
    Neurol Sci; 2019 Mar; 40(3):479-487. PubMed ID: 30535563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
    von Niederhäusern V; Ruder J; Ghraichy M; Jelcic I; Müller AM; Schanz U; Martin R; Trück J
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36229189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.